Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
13 evidence topics · 7 sources
Summary
- Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
- Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
- Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.
Lorundrostat subgroups in Launch-HTN: age, sex, race, body mass index, and number of background drugs
“The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat by chronic kidney disease status in Launch-HTN
Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12
| CKD stage | Lorundrostat 50 mg participants | Placebo-adjusted AOSBP change, mm Hg (95% CI) | Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg |
|---|---|---|---|
| No CKD | “N=406” | “-12.2 (-17.1, -7.3)” | “48.0” |
| Stage 1 | “N=58” | “-10.6 (-18.6, -2.6)” | “50.6” |
| Stage 2 | “N=31” | “-7.6 (-16.5, 1.4)” | “28.4” |
| Stage 3 | “N=38” | “-10.1 (-21.1, 1.0)” | “47.0” |
Lorundrostat by obesity and diuretic use in Target-HTN
“Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure decreases were attenuated among participants not taking a diuretic” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat by plasma renin status in Target-HTN
“Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lorundrostat in obstructive sleep apnea with obesity
Number of background antihypertensive drugs: class evidence used by ICER
Spironolactone response by plasma renin
“Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote